SuperworthIradimed profit margin IRMD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 26.7%
- Operating margin, 12 months
- 31.9%
- Net margin on a year earlier
- +0.1 pts
- Peer median
- 6.5%
Over the twelve months to Jun 30, 2026, Iradimed kept 26.7% of its revenue as net profit, with an operating margin of 31.9% and a gross margin of 75.9%.
Five years earlier its net margin was 12.9%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 26.8% | 31.2% | 76.7% |
| FY2024 | 26.3% | 30.0% | 76.9% |
| FY2023 | 26.2% | 30.6% | 76.5% |
| FY2022 | 24.1% | 29.3% | 77.4% |
| FY2021 | 22.3% | 23.5% | 76.6% |
| FY2020 | 4.3% | −2.4% | 74.3% |
| FY2019 | 25.0% | 22.5% | 77.1% |
| FY2018 | 20.7% | 19.7% | 76.3% |
| FY2017 | 2.2% | 5.6% | 75.9% |
| FY2016 | 22.2% | 33.6% | 81.1% |
| FY2015 | 23.8% | 36.4% | 81.5% |
| FY2014 | 13.1% | 19.6% | 78.3% |
| FY2013 | 17.1% | 24.6% | 74.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 26.7% | +0.1 pts | 31.9% | |
| Q1 FY26 | 27.4% | +1.0 pts | 32.4% | |
| Q4 FY25 | 26.8% | +0.6 pts | 31.2% | |
| Q3 FY25 | 26.3% | +0.2 pts | 30.9% | |
| Q2 FY25 | 26.6% | −0.2 pts | 30.7% | |
| Q1 FY25 | 26.3% | −0.2 pts | 30.1% | |
| Q4 FY24 | 26.3% | +0.0 pts | 30.0% | |
| Q3 FY24 | 26.1% | +0.2 pts | 29.9% | |
| Q2 FY24 | 26.8% | +2.3 pts | 30.9% | |
| Q1 FY24 | 26.5% | +2.1 pts | 30.7% | |
| Q4 FY23 | 26.2% | +2.2 pts | 30.6% | |
| Q3 FY23 | 25.9% | −0.0 pts | 30.4% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first, today.
| Company | Profit margin |
|---|---|
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| EYENational Vision | 2.5% |
| MOVMovado | 6.0% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| MDXGMimedx | 1.8% |
| TCMDTactile Systems Technology | 7.1% |
| UFPTUFP Technologies | 11.4% |
| Peer median | 6.5% |
Where Iradimed ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Iradimed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.